Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib with Palbociclib and Fulvestrant in HR+/HER2- Metastatic Breast Cancer
NCT03854903Phase 1Completed
- Sponsor
- Georgetown University
- Start
- Apr 2019
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bosutinib in breast cancer (4 arms), sponsored by Georgetown University. Primary endpoints: Toxicity of bosutinib in combination at 1 year, Incidence of adverse events at 1 year and 3 more. Started Apr 2019; status: completed.
02
Drugs
bosutinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03854903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03854903.